Among 25 analysts covering Abbott Laboratories (NYSE:ABT), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. Abbott Laboratories had 105 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, August 15 by Cowen & Co. The rating was reinitiated by Credit Suisse with “Outperform” on Monday, August 10. The rating was maintained by Jefferies on Thursday, August 4 with “Buy”. The firm has “Buy” rating by Cowen & Co given on Wednesday, October 18. On Thursday, September 28 the stock rating was maintained by Barclays Capital with “Overweight”. On Thursday, August 27 the stock rating was maintained by Wells Fargo with “Buy”. The rating was maintained by Jefferies on Tuesday, September 13 with “Buy”. The stock has “Buy” rating by Cowen & Co on Friday, September 22. The company was upgraded on Friday, February 5 by Argus Research. Stifel Nicolaus maintained it with “Buy” rating and $58 target in Thursday, July 23 report. See Abbott Laboratories (NYSE:ABT) latest ratings:
30/01/2018 Broker: Citigroup Old Rating: Neutral New Rating: Neutral Old Target: $59 New Target: $64 Maintain
30/01/2018 Broker: Argus Research Rating: Buy New Target: $80.0
25/01/2018 Broker: Barclays Capital Old Rating: Overweight New Rating: Overweight Old Target: $66 New Target: $70 Maintain
25/01/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $65 New Target: $69 Maintain
25/01/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $67 New Target: $70 Maintain
24/01/2018 Broker: RBC Capital Markets Rating: Buy New Target: $67.0 Maintain
25/01/2018 Broker: Wells Fargo Rating: Outperform Old Target: $66 New Target: $70 Maintain
25/01/2018 Broker: William Blair Rating: Buy Upgrade
25/01/2018 Broker: Guggenheim Rating: Buy New Target: $72.0 Maintain
24/01/2018 Broker: BMO Capital Markets Rating: Buy New Target: $70.0 Maintain
Analysts expect Allot Communications Ltd. (NASDAQ:ALLT) to report $-0.10 EPS on May, 8.They anticipate $0.03 EPS change or 23.08% from last quarter’s $-0.13 EPS. After having $-0.07 EPS previously, Allot Communications Ltd.’s analysts see 42.86% EPS growth. The stock increased 0.49% or $0.0264 during the last trading session, reaching $5.3664. About 8,602 shares traded. Allot Communications Ltd. (NASDAQ:ALLT) has risen 20.43% since April 17, 2017 and is uptrending. It has outperformed by 8.88% the S&P500.
Among 4 analysts covering Allot Communications (NASDAQ:ALLT), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Allot Communications had 6 analyst reports since September 1, 2015 according to SRatingsIntel. The rating was maintained by Oppenheimer with “Hold” on Tuesday, August 1. The firm earned “Hold” rating on Thursday, September 7 by Jefferies. The stock of Allot Communications Ltd. (NASDAQ:ALLT) earned “Buy” rating by Wunderlich on Thursday, October 29. The stock has “Market Perform” rating by Oppenheimer on Tuesday, September 1. The firm has “Hold” rating by Wunderlich given on Tuesday, May 3. As per Wednesday, February 7, the company rating was upgraded by Bank of America.
Allot Communications Ltd. provides visibility, intelligence, security, and monetization solutions that enable service providers and enterprises to protect and personalize the digital experience worldwide. The company has market cap of $180.25 million. The firm offers various platforms, including Allot Service Gateway 9500, Allot Service Gateway Tera, Allot Service Gateway, and Allot NetEnforcer for in-line deployment in traditional and virtualized network access infrastructure. It currently has negative earnings. It also provides subscriber management platforms, such as Allot TierManager, Allot QuotaManager, Allot ChargeSmart, and Allot Smart Engage Onboarding that drive centralized creation, provisioning, and pricing of subscriber services; and analytics solutions comprising Allot ClearSee Analytics and Allot ClearSee Data Source that analyze traffic data.
Investors sentiment increased to 1.4 in Q4 2017. Its up 0.20, from 1.2 in 2017Q3. It is positive, as 3 investors sold Allot Communications Ltd. shares while 7 reduced holdings. 8 funds opened positions while 6 raised stakes. 12.44 million shares or 0.69% more from 12.36 million shares in 2017Q3 were reported. California Employees Retirement System reported 10,800 shares or 0% of all its holdings. Paw reported 580,000 shares. 2.21M are owned by Clal Enterprise. 2,251 are owned by Comml Bank Of Montreal Can. Moreover, Essex Ltd Liability Co has 0.03% invested in Allot Communications Ltd. (NASDAQ:ALLT). Horrell Capital has invested 0.62% of its portfolio in Allot Communications Ltd. (NASDAQ:ALLT). 11,800 were accumulated by Oppenheimer & Co. 7,716 were accumulated by Morgan Stanley. Macquarie Group Inc accumulated 5,800 shares or 0% of the stock. Royal National Bank Of Canada reported 9,900 shares stake. Renaissance Technology Limited Liability invested in 0% or 850,700 shares. Fmr Ltd Liability Corp invested 0% in Allot Communications Ltd. (NASDAQ:ALLT). Spark Invest Management Limited Liability Corporation holds 10,800 shares or 0% of its portfolio. Deutsche Comml Bank Ag has 84,553 shares for 0% of their portfolio. Comml Bank Of America Corporation De has invested 0% of its portfolio in Allot Communications Ltd. (NASDAQ:ALLT).
Since October 23, 2017, it had 1 insider buy, and 19 insider sales for $28.95 million activity. Bracken Sharon J had sold 2,100 shares worth $126,559. Another trade for 459 shares valued at $27,213 was sold by PEDERSON MICHAEL J. 96,603 shares valued at $5.43 million were sold by Salvadori Daniel Gesua Sive on Monday, October 23. 1,645 shares valued at $96,728 were sold by BIRD ROGER on Wednesday, February 28. $2.69 million worth of Abbott Laboratories (NYSE:ABT) was sold by Ford Robert B on Tuesday, January 30. 56,401 shares valued at $3.36M were sold by Fussell Stephen R on Friday, February 16. Funck Robert E sold 1,220 shares worth $71,970.
Abbott Laboratories manufactures and sells health care products worldwide. The company has market cap of $104.06 billion. The companyÂ’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; MÃ©niÃ¨re's disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; cardiovascular and metabolic products; and influenza vaccines, as well as to regulate physiological rhythm of the colon. It has a 221.51 P/E ratio. The Company’s Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic tests; informatics and automation solutions; and a suite of informatics tools and professional services.
The stock increased 0.53% or $0.31 during the last trading session, reaching $59.58. About 2.32M shares traded. Abbott Laboratories (NYSE:ABT) has risen 34.85% since April 17, 2017 and is uptrending. It has outperformed by 23.30% the S&P500.